Logo image of MTNB

MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Fundamental Analysis

NYSEARCA:MTNB - NYSE Arca - US5768103039 - Common Stock - Currency: USD

0.812  +0.05 (+6.7%)

After market: 0.824 +0.01 (+1.48%)

Fundamental Rating

1

MTNB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of MTNB have multiple concerns. MTNB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTNB had negative earnings in the past year.
In the past year MTNB has reported a negative cash flow from operations.
In the past 5 years MTNB always reported negative net income.
MTNB had a negative operating cash flow in each of the past 5 years.
MTNB Yearly Net Income VS EBIT VS OCF VS FCFMTNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -191.84%, MTNB is doing worse than 89.48% of the companies in the same industry.
MTNB has a Return On Equity of -319.51%. This is in the lower half of the industry: MTNB underperforms 74.15% of its industry peers.
Industry RankSector Rank
ROA -191.84%
ROE -319.51%
ROIC N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
MTNB Yearly ROA, ROE, ROICMTNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

MTNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTNB Yearly Profit, Operating, Gross MarginsMTNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

MTNB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MTNB has been increased compared to 1 year ago.
The number of shares outstanding for MTNB has been reduced compared to 5 years ago.
MTNB has a worse debt/assets ratio than last year.
MTNB Yearly Shares OutstandingMTNB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
MTNB Yearly Total Debt VS Total AssetsMTNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -26.42, we must say that MTNB is in the distress zone and has some risk of bankruptcy.
MTNB's Altman-Z score of -26.42 is on the low side compared to the rest of the industry. MTNB is outperformed by 89.84% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MTNB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, MTNB perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.42
ROIC/WACCN/A
WACC10.01%
MTNB Yearly LT Debt VS Equity VS FCFMTNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.01 indicates that MTNB has no problem at all paying its short term obligations.
MTNB has a Current ratio of 3.01. This is in the lower half of the industry: MTNB underperforms 65.24% of its industry peers.
A Quick Ratio of 3.01 indicates that MTNB has no problem at all paying its short term obligations.
MTNB has a Quick ratio of 3.01. This is in the lower half of the industry: MTNB underperforms 63.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.01
Quick Ratio 3.01
MTNB Yearly Current Assets VS Current LiabilitesMTNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

MTNB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.18%, which is quite impressive.
Looking at the last year, MTNB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MTNB will show a very strong growth in Earnings Per Share. The EPS will grow by 57.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTNB Yearly Revenue VS EstimatesMTNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 200M 400M 600M
MTNB Yearly EPS VS EstimatesMTNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTNB Price Earnings VS Forward Price EarningsMTNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTNB Per share dataMTNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as MTNB's earnings are expected to grow with 30.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.59%
EPS Next 3Y30.93%

More info and screens

0

5. Dividend

5.1 Amount

MTNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MATINAS BIOPHARMA HOLDINGS I

NYSEARCA:MTNB (5/23/2025, 6:40:00 PM)

After market: 0.824 +0.01 (+1.48%)

0.812

+0.05 (+6.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-12 2025-08-12
Inst Owners6.87%
Inst Owner Change-11.84%
Ins Owners0.94%
Ins Owner Change0%
Market Cap4.13M
Analysts45.71
Price Target30.6 (3668.47%)
Short Float %1.73%
Short Ratio1.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.34%
Min EPS beat(2)9.67%
Max EPS beat(2)21.01%
EPS beat(4)4
Avg EPS beat(4)13.55%
Min EPS beat(4)1.96%
Max EPS beat(4)21.57%
EPS beat(8)8
Avg EPS beat(8)11.84%
EPS beat(12)11
Avg EPS beat(12)8.96%
EPS beat(16)14
Avg EPS beat(16)7.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-4.17
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS1.49
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -191.84%
ROE -319.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.03%
ROA(5y)-80.29%
ROE(3y)-165.34%
ROE(5y)-115.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.01
Quick Ratio 3.01
Altman-Z -26.42
F-Score1
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18%
EPS Next Y63.31%
EPS Next 2Y-10.59%
EPS Next 3Y30.93%
EPS Next 5Y57.54%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.97%
OCF growth 3YN/A
OCF growth 5YN/A